Tirzepatide is not recommended for individuals with a history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), severe hypersensitivity to the drug, severe gastrointestinal disease, or pancreatitis, as well as pregnant or breastfeeding women and those with severe kidney disease
Front Endocrinol 11:568861 Niu S, Chen S, Chen X, Ren Q, Yue L, Pan X, Zhao H, Li Z, Chen X (2022) Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
Research often uses a 12-week 5% loss as an early response marker, but not achieving that by week 12 does not mean treatment isnt workingmany people respond later as doses stabilize and routines lock in
Both have their merits
Lose body fat Its ironic, I know